Norplat 75mg Film-Coated Tablet

Pajjiż: Filippini

Lingwa: Ingliż

Sors: FDA (Food And Drug Administration)

Ingredjent attiv:

Clopidogrel (as bisulfate)

Disponibbli minn:

Getz Pharma (Phils.), Inc.

INN (Isem Internazzjonali):

Clopidogrel (as bisulfate)

Dożaġġ:

75mg

Għamla farmaċewtika:

Film-Coated Tablet

Unitajiet fil-pakkett:

Alu-Alu Blister Pack of 14's (Box of 28’s), Alu/Alu Blister pack x 7's (box of 28's)

Manifatturat minn:

Getz Pharma Pvt. Ltd., Pakistan

Data ta 'l-awtorizzazzjoni:

2023-11-30

Karatteristiċi tal-prodott

CONTRAINDICATIONS
Clopidogrel is contraindicated in:
-
Patients who have shown hypersensitivity to the drug
or any component of the medication.
-
Patients who suffer from active pathological bleeding
such as peptic ulcer or intracranial hemorrhage.
PRECAUTIONS
_General_
-
Clopidogrel should be used with caution in patients
who may be at risk of increased bleeding from trauma,
surgery, or other pathological conditions.
-
If a patient is to undergo elective surgery, consideration
should be given to stopping clopidogrel 5 days before
surgery.
-
Clopidogrel should be used with caution in patients
who have lesions with a propensity to bleed (such as
ulcers). Drugs that might induce such le
sions should
be used in caution in patients taking clopidogrel.
_Hematological_
Clopidogrel should not be administered to patients with
hematopoietic
disorders
such
as
neutropenia
o r
thrombocytopenia, hemorrhagic diathesis or other hemorrhagic
disorders associated with a prolonged bleeding time. Full blood
count should be performed before starting treatment and every
two weeks during the first three months of therapy. If clopidogrel
is discontinued during this period, a full blood count should be
performed within two weeks of stopping treatment.
_Hepatic Impaired Patients_
Experience is limited in patients with severe hepatic disease,
who may have bleeding diatheses. Clopidogrel should be used
with caution in such patients.
_Renal Impaired Patients_
Experience is limited in patients with severe renal impairment.
Clopidogrel
should be used with caution in such patients.
_Pediatric Use_
Safety and effectiveness in the population have not been
established.
_Pregnancy_
Clopidogrel has not been studied in pregnant women. It should
be used during
pregnancy only
if
clearly needed.
_Nursing Mothers_
It is not known if clopidogrel is excreted in human milk. Because
many drugs are excreted in human milk, caution should be
exercised when clopidogrel is given to a nursing mother.
DRUG INTERACTIONS
_Aspirin:_ A pharmacodynamic interaction betwe